Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lycorine hydrochloride in treatment of pulmonary fibrosis

A technology of lycorine hydrochloride and pulmonary fibrosis, which is applied in the directions of medical preparations containing active ingredients, respiratory diseases, organic active ingredients, etc.

Inactive Publication Date: 2017-08-18
CHINA PHARM UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Up to now, there is no related report that lycorine hydrochloride can inhibit TGF-β signaling pathway and slow down pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lycorine hydrochloride in treatment of pulmonary fibrosis
  • Application of lycorine hydrochloride in treatment of pulmonary fibrosis
  • Application of lycorine hydrochloride in treatment of pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1 Lycorine Hydrochloride Inhibits Myofibroblast Differentiation Induced by TGF-β1

[0016] The cells used in this example were the mouse lung fibroblast cell line Mlg obtained from the American Type Culture Collection (ATCC). After Mlg fibroblasts were overgrown, 0.1% serum was treated for 24 hours, and 5 ng / mL LTGF-β1 protein and a final concentration of 5 μmol / L lycorine hydrochloride or the same volume of DMSO were added as control. After 12 hours of treatment, RNA was collected for real-time fluorescent quantitative PCR to detect α-SMA; after 24 hours of treatment, cells were collected and Western Blotting was used to detect the expression of α-SMA protein. Real-time fluorescent quantitative PCR refers to preparing total RNA from cells using Trizol (Invitrogen), synthesizing cDNA using ThermoScript RT-PCR kit (Invitrogen), and detecting the expression of α-SMA using SYBR Green kit (Roche). Relative gene expression using 2 -Δ(ΔCT) method, and β-actin was us...

Embodiment 2

[0023] Example 2 Lycorine hydrochloride slows down bleomycin-induced pulmonary fibrosis

[0024] Pulmonary fibrosis animal model preparation refers to male C57BL / 6J (age 8-10 weeks) wild-type mice, anesthetized mice with 0.6mL / 100g intraperitoneal (I.P.) injection of 7.5% chloral hydrate, intratracheal injection of Bray Mycin 2.5U / kg. The specific scheme is as follows: after weighing and recording the body weight, fix the mouse on the operating table, disinfect the neck with 70% alcohol, use a scalpel to cut vertically about 1 cm in the neck of the mouse, use micro-tweezers to separate the tissue to expose the trachea, Insert the syringe into the trachea through the gap between the cartilage rings of the trachea towards the end of the heart, then slowly inject 2.5 U / kg of bleomycin physiological saline solution in a volume appropriate to its body weight, and immediately turn the animal upright and rotate left and right to make the liquid medicine Evenly distributed in the lun...

Embodiment 3

[0032] Preparations of lycorine hydrochloride

[0033] Lycorine Hydrochloride Tablets

[0034] Lycorine hydrochloride 5mg, starch 92g, magnesium stearate 3g

[0035] Preparation process: take lycorine hydrochloride and pass through a 100-mesh sieve, add starch and magnesium stearate, mix evenly, make granules, dry, and press into tablets.

[0036] Lycorine Hydrochloride Capsules

[0037] Lycorine hydrochloride 5mg, pregelatinized starch 92g, magnesium stearate 3g

[0038] Preparation process: take lycorine hydrochloride and pass through a 100-mesh sieve, add pregelatinized starch and magnesium stearate, mix evenly, make granules, dry, pack into capsules, and obtain.

[0039] Lycorine Hydrochloride Injection

[0040] Lycorine hydrochloride 43mg, sodium chloride for injection 7mg

[0041] Preparation process: take lycorine hydrochloride through a 100-mesh sieve, add 1.9mL of water for injection to dissolve, add sodium chloride for injection to make it isotonic, adjust the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of lycorine hydrochloride in preparation of drugs for treating pulmonary fibrosis. A great application prospect is provided for treatment, remission or improvement of a fibrotic lung disease or symptom.

Description

technical field [0001] The invention relates to a new application of Lycorine chloride, in particular to the application of Lycorine hydrochloride in the treatment of pulmonary fibrosis. Background technique [0002] The occurrence of pulmonary fibrosis is related to many factors, including smoking, air pollution, autoimmune diseases, viruses, inappropriate treatment methods, etc. For example, SARS virus can cause fibrosis in some patients, and the use of a large amount of antibiotics during treatment can accelerate the process of fibrosis, leading to serious sequelae. Idiopathic pulmonary fibrosis (IPF) is the most common, most serious, and most refractory disease among pulmonary fibrosis diseases. Qualitative lung disease. It is characterized by massive accumulation of myofibroblasts and excessive accumulation of extracellular matrix (ECM) such as collagen, which spreads and expands fibrotic foci in the lung interstitium. Under the low power microscope, the lung tissue ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/437A61P11/00
CPCA61K31/437
Inventor 徐晓军杨华张鑫
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com